AKTX · ISSUER CIK 1541157
Akari Therapeutics Plc
Between Aug 1, 2026 and Oct 29, 2026, 7 Akari Therapeutics Plc insiders reported $0.00 of open-market purchases and $0.00 of sales on SEC Form 4.
↗7 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. No open-market sales in the window.
$0.00Insider buying
$0.00Insider selling
$0.00Net open-market
Oct 16, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 16, 202617:20 | Oct 5, 2026from Aug 18, 2026 | AKTX | Director | A · GrantLate 11d | $7.90 | +12,312 | 76,861 | +19% | $97K | ||
| Oct 16, 202617:20 | Oct 5, 2026from Aug 18, 2026 | AKTX | Director, 10% Owner | A · GrantLate 11d | $7.90 | +23,409 | 140,805 | +20% | $185K | ||
| Oct 16, 202617:20 | Oct 14, 2026 | AKTX | Director | M · Exercise | $0.00 | +10,052 | 38,877 | +35% | $4.02 | ||
| Oct 16, 202617:20 | Oct 5, 2026from Aug 18, 2026 | AKTX | Director | A · GrantLate 11d | $7.90 | +16,413 | 28,825 | +132% | $130K | ||
| Oct 16, 202617:20 | Oct 14, 2026 | AKTX | Director | M · Exercise | $0.00 | +3,866 | 22,759 | +20% | $1.55 | ||
| Oct 16, 202617:20 | Oct 5, 2026from Aug 18, 2026 | AKTX | Director | A · GrantLate 11d | $7.90 | +17,777 | 18,893 | +1593% | $140K | ||
| Oct 16, 202617:20 | Oct 14, 2026 | AKTX | CEO, Director | M · Exercise | $0.00 | +27,066 | 41,173 | +192% | $10.83 | ||
| Oct 16, 202617:20 | Oct 5, 2026from Aug 18, 2026 | AKTX | Director | A · GrantLate 11d | $7.90 | +8,536 | 12,102 | +239% | $67K | ||
| Oct 1, 202616:50 | Sep 29, 2026 | AKTX | CEO, Director | A · Grant | $9.72 | +6,430 | 14,107 | +84% | $62K | ||
| Aug 19, 202617:00 | Aug 17, 2026 | AKTX | Interim CFO | A · Grant | $7.52 | +1,728 | 23,309 | +8% | $13K | ||
| Aug 5, 202618:30 | Jul 16, 2026 | AKTX | Interim CFO | A · GrantLate 20d | $11.50 | +1,130 | 21,581 | +6% | $13K |